A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
← catalyst calendarNCT07624305 · readout in 1,412 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
2,800estimated
Sites
45
Countries
Argentina, Canada, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-01 | estimated | When the study began enrolling |
| Primary completion | 2030-07-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Renal Insufficiency, Chronic
Interventions
- Drug: Balcinrenone/dapagliflozin
- Drug: Dapagliflozin
Primary outcome
what the primary-completion date above is the date OFTime from randomization to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event
measured Up to 46 months.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed